|
Ozanezumab is a monoclonal antibody designed for the treatment of ALS and multiple sclerosis.〔(Statement On A Nonproprietary Name Adopted By The USAN Council - Ozanezumab ), ''American Medical Association''.〕 Ozanezumab targets a protein called Neurite Outgrowth Inhibitor (NOGO-A) or Reticulon 4. NOGO-A is a protein that in humans is encoded by the RTN4 gene that has been identified as an inhibitor of neurite outgrowth specific to the central nervous system. NOGO-A is found at higher than normal levels in persons with MND.〔What is MND?〕 This drug was developed by GlaxoSmithKline under the identifier GSK 1223249. ==Mechanism== From an announced phase II clinical trial by GSK (): "NOGO-A blocks neurons from growing toward muscle once the connection has been made. When motor neurons degenerate and the connection becomes weakened, NOGO-A would work against keeping that nerve/muscle contact strong. Increased NOGO-A has been observed in muscle of people with ALS and ozanezumab delayed symptom onset and improved survival in ALS model mice. Thus, it is hoped that it will preserve muscle function and slow the rate of ALS progression in humans." Nature article about the mechanism behind this ( Jokic, 2006 ). Another article on the subject is ( Smidt(2009), Axon guidance proteins - Novel therapeutic targets for ALS ) There is an audio podcast about NOGO-A and Ozanezumab by an expert available (here ). 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Ozanezumab」の詳細全文を読む スポンサード リンク
|